SCHEMBL361838

SCHEMBL361838

COc1cc(CC=O)c([N+](=O)[O-])cc1OCCCN1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CHEK1 O14757 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 2/20 0.46
LMNA P02545 1/20 0.45
TDP1 Q9NUW8 2/20 0.43
HTT P42858 1/20 0.42
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
SRC P12931 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27958219 0.88 CYP2D6 (0.66) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL4317372 0.85 ALDH1A1 (0.57) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL6508978 0.85 ALDH1A1 (0.57) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL362446 0.83 TSHR (0.49) CYP2D6KDM4ECHEK1TSHRLMNA
SCHEMBL31016516 0.81 ALDH1A1 (0.55) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL13388207 0.80 CYP2D6 (0.56) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL7526518 0.80 KDM4E (0.64) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL5567501 0.80 KDM4E (0.64) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL3280339 0.80 CYP2D6 (0.56) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E
SCHEMBL361837 0.80 KDM4E (0.58) CYP2D6CYP1A2CYP2C19ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2768796-A1 PROCESS FOR PREPARING QUINOLINE DERIVATIVES Exelixis, Inc. (US) 2014-08-27 EP disclosed
EP-2621482-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES Exelixis, Inc. (US) 2013-08-07 EP disclosed
EP-2621483-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES Exelixis, Inc. (US) 2013-08-07 EP disclosed
EP-2593091-A1 C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS Exelixis, Inc. (US) 2013-05-22 EP disclosed
WO-2013059788-A1 PROCESS FOR PREPARING QUINOLINE DERIVATIVES EXELIXIS, INC. (US) 2013-04-25 WO disclosed
WO-2012044574-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES EXELIXIS, INC. (US) 2012-04-05 WO disclosed
WO-2012044577-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES EXELIXIS, INC. (US) 2012-04-05 WO disclosed
WO-2012009723-A1 C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS EXELIXIS, INC. (US) 2012-01-19 WO disclosed
EP-2350011-A1 METHODS OF PREPARING QUINOLINE DERIVATIVES Exelixis, Inc. (US) 2011-08-03 EP disclosed
WO-2010056960-A1 METHODS OF PREPARING QUINOLINE DERIVATIVES EXELIXIS INC. (US) 2010-05-20 WO disclosed